Parabilis Medicines (NASDAQ:PBLS) Upgraded to “Strong-Buy” at Guggenheim

Guggenheim upgraded shares of Parabilis Medicines (NASDAQ:PBLS) to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research firms have also weighed in on PBLS. Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a research note on Saturday, June 20th. Evercore began coverage on shares of Parabilis Medicines in a research report on Monday. They issued an “outperform” rating on the stock. Bank of America assumed coverage on shares of Parabilis Medicines in a report on Monday. They issued a “buy” rating and a $45.00 price target for the company. Finally, Leerink Partners started coverage on shares of Parabilis Medicines in a research report on Monday. They set an “outperform” rating and a $40.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to MarketBeat.com, Parabilis Medicines currently has a consensus rating of “Buy” and a consensus price target of $41.67.

Parabilis Medicines Trading Up 1.5%

Shares of NASDAQ PBLS traded up $0.43 during trading on Monday, reaching $29.63. The stock had a trading volume of 110,360 shares, compared to its average volume of 939,208. Parabilis Medicines has a one year low of $24.51 and a one year high of $34.47.

Insider Transactions at Parabilis Medicines

In other Parabilis Medicines news, major shareholder Guy Levy purchased 500,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the insider owned 1,027,000 shares in the company, valued at approximately $20,540,000. This represents a 94.88% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan Sebulsky acquired 12,500 shares of Parabilis Medicines stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $20.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the director owned 12,500 shares of the company’s stock, valued at approximately $250,000. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 530,000 shares of company stock valued at $10,723,528 over the last three months.